First patient enrolled in the Kiobrina® phase III study
The first patient has been enrolled in the phase III study with Kiobrina®(rhBSSL) which is designed to evaluate efficacy, safety and tolerability ofKiobrina® in the treatment of preterm infants. Kiobrina® is a recombinantproduced human bile-salt stimulated lipase (rhBSSL) developed by Sobi to improvegrowth in preterm infants who receive pasteurized breast milk or infant formula. The phase III study is a multicenter, double- blind, placebo-controlled studywhere preterm infants younger than 32 weeks of gestational age are randomized toreceive rhBSSL or placebo added to preterm formula